Evaluating Neoantigen-Reactive CISH-Knockout TILs in Metastatic Colorectal Cancer

Branden Moriarity, PhD, associate professor, Division of Pediatric Hematology/Oncology, co-director, Center for Genome Engineering, Genome Engineering Shared Resource (GESR), member, Center for Genome Engineering, University of Minnesota, member, Stem Cell Institute, Masonic Cancer Center; Beau Webber, PhD, associate professor. Division of Pediatric Hematology/Oncology, co-director, GESR, member, Stem Cell Institute, University of Minnesota Medical School, member, Masonic Cancer Center.

CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD

ByBranden Moriarity, PhD,Beau Webber, PhD

July 28th 2025

Drs Moriarity and Webber discuss a study evaluating neoantigen-reactive CISH knockout TIL therapy in patients with metastatic gastrointestinal cancers.

First-in-Human Data Support CISH Knockout Strategy to Enhance TIL Activity, Circumvent ICI Resistance in Metastatic GI Cancers

ByCourtney Flaherty

June 20th 2025

Emil Lou, MD, PhD, FACP, discusses the potential applicability of CRISPR-Cas9–mediated CISH knockout to bolster TIL responses in drug-refractory GI tumors.

Neoantigen-Reactive TILs With CISH Knockout Are Safe and Effective in Metastatic GI Tumors

ByAshling Wahner

May 29th 2025

CRISPR-Cas9–mediated CISH gene knockout TIL therapy was well tolerated and demonstrated early signals of efficacy in metastatic GI epithelial cancer.

Evaluating Neoantigen-Reactive CISH-Knockout TILs in Metastatic Colorectal Cancer

CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD

First-in-Human Data Support CISH Knockout Strategy to Enhance TIL Activity, Circumvent ICI Resistance in Metastatic GI Cancers

Neoantigen-Reactive TILs With CISH Knockout Are Safe and Effective in Metastatic GI Tumors

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL